Cosychem has a proprietary library of over 10,000 ionizable lipids. By tuning lipid structures or formulations, we achieve highly efficient, tissue-specific delivery to the liver, lungs, spleen, muscle, and other tissues. In vivo toxicology data show that our high-performance lipids offer a 50–100 times wider safety window than standard compounds. We provide comprehensive delivery solutions for nucleic acid therapeutics (siRNA, mRNA), gene editing, gene regulation therapies, and multi-organ targeting.
For different nucleic acid modalities (mRNA, siRNA, circRNA, etc.) and therapeutic applications (vaccines, cancer immunotherapy, gene editing), we optimize lipid structures, formulation ratios, particle size, and surface modifications to enhance targeting and stability.
Microfluidic synthesis enables scalable production from μg-level lab research to g-level clinical supply with excellent batch consistency.
LNP in vitro stability studies, safety profiling, and toxicity assessments reduce immunogenicity and off-target risks.
Tailor-made chemistry for the four key LNP components — ionizable lipids, helper lipids, cholesterol, and PEG-lipids — supporting novel molecular library expansion and derivative development.
Based on a proprietary delivery platform, we provide flexible licensing and customized IP transformation services for ionizable lipids and LNP formulations.